Cargando…

Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition

This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guang...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Wenhua, Guo, Minzhang, Pan, Zhenkui, Cai, Xiuyu, Li, Caichen, Zhao, Yi, Liang, Hengrui, Yang, Haiying, Wang, Zhen, Chen, Wenting, Xu, Chuhong, Yang, Xinyun, Sun, Jianyu, He, Ping, Gu, Xia, Yin, Weiqiang, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549909/
https://www.ncbi.nlm.nih.gov/pubmed/31033100
http://dx.doi.org/10.1111/cas.14032
_version_ 1783424089348636672
author Liang, Wenhua
Guo, Minzhang
Pan, Zhenkui
Cai, Xiuyu
Li, Caichen
Zhao, Yi
Liang, Hengrui
Yang, Haiying
Wang, Zhen
Chen, Wenting
Xu, Chuhong
Yang, Xinyun
Sun, Jianyu
He, Ping
Gu, Xia
Yin, Weiqiang
He, Jianxing
author_facet Liang, Wenhua
Guo, Minzhang
Pan, Zhenkui
Cai, Xiuyu
Li, Caichen
Zhao, Yi
Liang, Hengrui
Yang, Haiying
Wang, Zhen
Chen, Wenting
Xu, Chuhong
Yang, Xinyun
Sun, Jianyu
He, Ping
Gu, Xia
Yin, Weiqiang
He, Jianxing
author_sort Liang, Wenhua
collection PubMed
description This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guangzhou Medical University was investigated. The specimens were subjected to hybridization capture and sequence of 8 important NSCLC‐related driver genes. In addition, the slides were tested for PD‐L1, excision repair cross‐complementation group 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthase (TS) and β‐tubulin III by immunohistochemical staining. A total of 498 (63.4%) patients had at least 1 driver gene alteration. Wild‐type, EGFR rare mutation (mut), ALK fusion (fus), RAS mut, RET fus and MET mut had relatively higher proportions of lower ERCC1 expression. EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus, HER2 mut, ROS1 fus and MET mut were more likely to have TS low expression. Wild‐type, EGFR L858R, EGFR rare mut and BRAF mut were associated with lower β‐tubulin III expression. In addition, wild‐type, RAS mut, ROS1 fus, BRAF and MET mut had higher proportion of PD‐L1 high expression. As a pilot validation, 21 wild‐type patients with advanced NSCLC showed better depth of response and response rate to taxanes compared with pemetrexed/gemcitabine (31.2%/60.0% vs 26.6%/45.5%). Our study may aid in selecting the optimal salvage regimen after targeted therapy failure, or the chemo‐regimen where targeted therapy has not been a routine option. Further validation is warranted.
format Online
Article
Text
id pubmed-6549909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65499092019-06-07 Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition Liang, Wenhua Guo, Minzhang Pan, Zhenkui Cai, Xiuyu Li, Caichen Zhao, Yi Liang, Hengrui Yang, Haiying Wang, Zhen Chen, Wenting Xu, Chuhong Yang, Xinyun Sun, Jianyu He, Ping Gu, Xia Yin, Weiqiang He, Jianxing Cancer Sci Original Articles This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guangzhou Medical University was investigated. The specimens were subjected to hybridization capture and sequence of 8 important NSCLC‐related driver genes. In addition, the slides were tested for PD‐L1, excision repair cross‐complementation group 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthase (TS) and β‐tubulin III by immunohistochemical staining. A total of 498 (63.4%) patients had at least 1 driver gene alteration. Wild‐type, EGFR rare mutation (mut), ALK fusion (fus), RAS mut, RET fus and MET mut had relatively higher proportions of lower ERCC1 expression. EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus, HER2 mut, ROS1 fus and MET mut were more likely to have TS low expression. Wild‐type, EGFR L858R, EGFR rare mut and BRAF mut were associated with lower β‐tubulin III expression. In addition, wild‐type, RAS mut, ROS1 fus, BRAF and MET mut had higher proportion of PD‐L1 high expression. As a pilot validation, 21 wild‐type patients with advanced NSCLC showed better depth of response and response rate to taxanes compared with pemetrexed/gemcitabine (31.2%/60.0% vs 26.6%/45.5%). Our study may aid in selecting the optimal salvage regimen after targeted therapy failure, or the chemo‐regimen where targeted therapy has not been a routine option. Further validation is warranted. John Wiley and Sons Inc. 2019-05-22 2019-06 /pmc/articles/PMC6549909/ /pubmed/31033100 http://dx.doi.org/10.1111/cas.14032 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Liang, Wenhua
Guo, Minzhang
Pan, Zhenkui
Cai, Xiuyu
Li, Caichen
Zhao, Yi
Liang, Hengrui
Yang, Haiying
Wang, Zhen
Chen, Wenting
Xu, Chuhong
Yang, Xinyun
Sun, Jianyu
He, Ping
Gu, Xia
Yin, Weiqiang
He, Jianxing
Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title_full Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title_fullStr Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title_full_unstemmed Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title_short Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
title_sort association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549909/
https://www.ncbi.nlm.nih.gov/pubmed/31033100
http://dx.doi.org/10.1111/cas.14032
work_keys_str_mv AT liangwenhua associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT guominzhang associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT panzhenkui associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT caixiuyu associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT licaichen associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT zhaoyi associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT lianghengrui associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT yanghaiying associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT wangzhen associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT chenwenting associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT xuchuhong associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT yangxinyun associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT sunjianyu associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT heping associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT guxia associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT yinweiqiang associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition
AT hejianxing associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition